Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ho Wai Siu"'
Autor:
Derrick Ho Wai Siu, Robert Sean O'Neill, Carole A Harris, Justine Wang, Luke Ardolino, Teesha Downton, Matthew Tong, Jun Hee Hong, Venessa Chin, Philip R Clingan, Morteza Aghmesheh, Hussein Soudy
Publikováno v:
Immunotherapy. 14(7)
Immune checkpoint inhibitors have been incorporated into the treatment of various malignancies. An increasing body of literature is reporting rare but potentially fatal adverse events associated with these agents. In this case series, the authors rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1a6da22ab564a829288e9dd5bbb16b
https://pubmed.ncbi.nlm.nih.gov/35321560
https://pubmed.ncbi.nlm.nih.gov/35321560
Autor:
Hussein Soudy, Morteza Aghmesheh, Carole A. Harris, Matthew Tong, Robert S O'Neill, Ho Wai Siu, JunHee Hong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The use of immune checkpoint inhibitors (ICIs) against programmed cell death protein -1 (PD-1), its ligand (PD-L1) and cytotoxic T- lymphocyte associated protein 4 (CTLA4) have been increasing. Immune induced myocarditis, myositis and myas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad42aef35a0c6bbd2f56cff131cad84
https://doaj.org/article/dd4c162b9c054ccfa3132adf1de9fc4a
https://doaj.org/article/dd4c162b9c054ccfa3132adf1de9fc4a
Publikováno v:
Cancers. 14:1406
Angiogenesis inhibitors have been adopted into the standard armamentarium of therapies for advanced-stage renal cell carcinomas (RCC), but more recently, combination regimens with immune checkpoint inhibitors have demonstrated better outcomes. Despit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b44420b3496810e47f16c5df67b7f81
https://doi.org/10.3390/cancers14061406
https://doi.org/10.3390/cancers14061406
Autor:
Lawrence Kasherman, Sarah J. Lord, Ian C. Marschner, Craig R. Lewis, Michael Friedlander, Kirsty Lee, Derrick Ho Wai Siu, Chee Khoon Lee
Publikováno v:
Journal of geriatric oncology. 11(3)
There is uncertainty whether older patients derive a similar benefit from immune checkpoint inhibitors (ICI) as younger patients. We performed a meta-analysis of ICI trials in advanced cancers to better estimate treatment benefit in the older populat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::118390a35f9f1f78976f704e735c550c
https://pubmed.ncbi.nlm.nih.gov/31129081
https://pubmed.ncbi.nlm.nih.gov/31129081